Steigerwald Gordon & Koch Inc. Purchases 41,959 Shares of Pfizer Inc. (NYSE:PFE)

Steigerwald Gordon & Koch Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 457,464 shares of the biopharmaceutical company’s stock after purchasing an additional 41,959 shares during the period. Steigerwald Gordon & Koch Inc.’s holdings in Pfizer were worth $13,239,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PFE. Wasatch Advisors LP increased its stake in Pfizer by 21.0% during the fourth quarter. Wasatch Advisors LP now owns 167,300 shares of the biopharmaceutical company’s stock worth $4,817,000 after acquiring an additional 29,000 shares during the last quarter. Icon Wealth Advisors LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $479,000. Redwood Investment Management LLC grew its stake in shares of Pfizer by 1.8% during the fourth quarter. Redwood Investment Management LLC now owns 81,252 shares of the biopharmaceutical company’s stock valued at $2,339,000 after buying an additional 1,465 shares during the last quarter. Pinnacle Holdings LLC grew its stake in shares of Pfizer by 24.0% during the fourth quarter. Pinnacle Holdings LLC now owns 6,712 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 1,300 shares during the last quarter. Finally, New England Asset Management Inc. boosted its holdings in shares of Pfizer by 1.6% in the fourth quarter. New England Asset Management Inc. now owns 170,098 shares of the biopharmaceutical company’s stock valued at $4,897,000 after purchasing an additional 2,743 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 2.2 %

Shares of PFE stock traded down $0.65 during trading hours on Thursday, reaching $29.54. 14,971,007 shares of the company’s stock were exchanged, compared to its average volume of 37,327,754. The stock’s 50 day moving average is $29.09 and its 200-day moving average is $28.36. The company has a market cap of $167.39 billion, a price-to-earnings ratio of -496.00, a P/E/G ratio of 1.23 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 earnings per share. Analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.69%. Pfizer’s payout ratio is -2,800.00%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PFE. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.